A Feasibility Study Investigating Chemotherapy-induced Neuropathy Using Multi-frequency Tactilometry and Patient-reported Outcomes (PRO)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

32 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-11-20

Study Completion Date

2021-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chemotherapy induced peripheral neuropathy (CIPN) is among the most feared side effects to cancer treatment. The development of CIPN can lead to discontinuation or omission of antineoplastic drugs, possibly affecting efficacy of cancer treatment. There is a lack of knowledge about the natural course of CIPN and to this date, there are no available methods for the early detection of CIPN. With no effective prevention or treatment options, the condition has severe impact on patient quality of life and healthcare expenditure.

This study will investigate the natural course of paclitaxel- and oxaliplatin induced peripheral neuropathy using novel diagnostic techniques. Multi-frequency vibrational technology has provided an objective method for the early detection of diabetic neuropathy. Our study will test the feasibility of this method within the field of clinical oncology and CIPN.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Chemotherapy Induced Peripheral Neuropathy (CIPN)

NCT03272919

Chemotherapy-induced Peripheral Neuropathy

COMPLETED NA

Clinician Decision Support Algorithm for Chemotherapy-Induced Peripheral Neuropathy

NCT03514680

Cancer Chemotherapy-induced Peripheral Neuropathy

COMPLETED NA

Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longitudinal Single Center Feasibility Study

NCT06162403

Peripheral Nerve Stimulation Chemotherapy-induced Peripheral Neuropathy

RECRUITING NA

Effect of Transcutaneous Electrical Nerve Stimulation on CIPN Symptoms

NCT06499103

Chemotherapy-induced Peripheral Neuropathy

COMPLETED NA

Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer

NCT04563130

Gynecologic Cancer Chemotherapy-induced Peripheral Neuropathy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chemotherapy-induced Peripheral Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Paclitaxel

Patients scheduled to receive paclitaxel as part of their standard treatment

QST and PRO measurements during treatment

Intervention Type OTHER

We will observe the natural course of CIPN using multiple measurements

Oxaliplatin

Patients scheduled to receive oxaliplatin as part of their standard treatment

QST and PRO measurements during treatment

Intervention Type OTHER

We will observe the natural course of CIPN using multiple measurements

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

QST and PRO measurements during treatment

We will observe the natural course of CIPN using multiple measurements

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥ 18 years of age
* A diagnosis of cancer.
* Fulfil the criteria for starting chemotherapy.
* Scheduled to undergo at least 4 courses of paclitaxel- or oxaliplatin-based chemotherapy.
* No prior paclitaxel, oxaliplatin or other neurotoxic chemotherapy.